Clinical trials: Myeloid Leukemia in Relapse (Disorder)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Trial name
- NCT04639024
- Testing
- ADCT-301
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gwynn Long, M.D.
Acute Myeloid Leukemia
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Selinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial…
- Trial name
- NCT02416908
- Testing
- Selinexor, Cladribine, G-CSF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Chronic Myeloid Leukemia
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
This is a phase II efficacy (indicates the capacity for beneficial change or therapeutic effect) and safety study of Dasatinib in patients with relapsed Chronic Myeloid Leukemia (CML) following a Stem Cell Transplant (SCT) and…
- Trial name
- Dasatinib (NCT00895297)
- Testing
- Dasatinib (Sprycel)
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 50 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ipilimumab and how well it works in treating patients with high-risk myelodysplastic syndrome or acute myeloid leukemia that has come back or no longer responds to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT01757639
- Testing
- Ipilimumab, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
For newly diagnosed high-relapse-risk CEBPA mutant acute myeloid leukemia patients, we aim to perform allogeneic hematopoietic stem cell transplantation after patients finished one cycle of induction and two cycles of…
- Trial name
- NCT06458257
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Leukemia
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of MEK162 that can be given to patients with advanced leukemia. This is an investigational study.
- Trial name
- NCT02089230
- Testing
- MEK 162
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory…
- Trial name
- NCT03922100
- Testing
- NMS-03592088
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 63 people
- Sponsor
- Nerviano Medical Sciences
Leukemia, Myelodysplastic Syndromes
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacytidine work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00624936
- Testing
- Vidaza, Velcade
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia, Lymphoma
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment…
- Trial name
- NCT00897767
- Testing
- biologic sample preservation procedure
- Where
- 214 sites in United States
- Volunteers
- 1,873 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
The goal of this clinical research study is to learn if the combination of clofarabine, idarubicin, and cytarabine, or the combination of fludarabine, idarubicin, and cytarabine can help control Acute myeloid leukemia (AML) and…
- Trial name
- NCT01289457
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed).
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03661307
- Testing
- Decitabine, Quizartinib, Venetoclax
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00702403
- Testing
- nilotinib, imatinib mesylate, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory…
- Trial name
- NCT03896854
- Testing
- CART-19
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Leukemia
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients with chronic myelogenous…
- Trial name
- NCT00345826
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to…
- Trial name
- NCT05222984
- Testing
- Decitabine, Navitoclax, Venetoclax
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
This is a single-center randomized phase 2 open-label clinical trial.
- Conditions
- Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
- Trial name
- NCT07710534
- Testing
- Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Acute Myeloid Leukemia
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute…
- Trial name
- NCT04884984
- Testing
- anti-CLL1 CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and…
- Trial name
- NCT05886491
- Testing
- GDX012, Chemotherapy Agents
- Where
- 11 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
Acute Myeloid Leukemia
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
This study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either with a transplantation of…
- Trial name
- NCT00342316
- Testing
- Reduced Intensity Conditioning Stem Cell Transplantation
- Where
- 25 sites in Australia, Canada and 7 more
- Volunteers
- 340 people
- Sponsor
- Vastra Gotaland Region
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.